Crist Urges FDA to Move Quickly to Authorize Vaccines for Children Under 12

Calls for “Emergency Use” Authorization

Washington, DC – As COVID cases surge among children, U.S. Representative Charlie Crist (D-St. Petersburg) sent a letter to Acting Commissioner Janet Woodcock of the Food and Drug Administration (FDA) urging the expeditious and safe authorization of vaccines for children under the age of 12.

In the letter, Congressman Crist pushes for emergency use authorization for the COVID-19 vaccine among children under 12 if the vaccine meets the FDA’s rigorous safety and efficacy standards. He highlights the harm of Florida’s COVID wave, including school closures and full ICUs. School-age children now constitute 15.1% of all nation-wide COVID cases, with the threat growing as students have returned to in-person learning. 

“The past 18 months have been very difficult on families, especially families with young children. As we get children back into the classroom, they deserve every possible protection we can provide them, not just for their safety, but for their families and teachers,” said Rep. Crist. “While we can take steps like testing and mask wearing indoors, nothing compares to a vaccine. That’s why I’m calling on the FDA to complete its work studying the COVID vaccine for children under 12. A safe and effective and effective vaccine will help keep schools open and safe for children, their families, their teachers, and our communities.” 

A PDF of the letter can be found here, with text appearing below:

September 13, 2021

Janet Woodcock, MD
Acting Commissioner
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Dear Acting Commissioner Woodcock,

I write to urge you to take every appropriate step within your power to authorize a safe and effective COVID-19 vaccine for children under 12, particularly for our school age children who have returned to in-person learning.

As you know, the pandemic’s impact on children has dramatically increased. As of September 2nd, over five million cases were reported in children, representing 15.1 percent of total nationwide cases. This alarming increase in child cases is in large part driven by the lack of an approved vaccine for children, combined with the return of in-person learning. Social isolation, missed school, difficulties finding affordable childcare, and the added stress of the pandemic have profoundly affected families over the past 18 months. Community leaders, health officials, parents, teachers, and school administrators have been working to create safe, in-person learning environments for our children. While there are things we can do right now to keep children safe, including requiring vaccinations for adults who work with children and wearing masks indoors at schools, nothing compares to a safe, effective COVID-19 vaccine.

I understand that the Food and Drug Administration (FDA) has been working hard to approve a COVID-19 vaccine that is safe and effective for children under 12. As you can imagine, parents are eager for the FDA to reach a favorable conclusion as soon as possible, consistent with FDA’s gold standard scientific process. At the same time, many are worried that a vaccine may not be available before the end of the calendar year, given reports that the FDA is requesting manufacturers extend and expand their trials. I would urge the FDA to carefully consider the costs and benefits of expanding the trials, rather than using existing data from the initial cohort.

As you know, children are not just at risk of getting the virus. Infected children can spread the virus to other children, teachers, and immunocompromised adults at home. With my home State of Florida struggling with its worst COVID surge to date, and our Governor recklessly playing politics with masks in schools and downplaying the importance of vaccines, there is a devastating cost to delay. In Florida, we have seen pediatric ICUs near capacity, with more than 13,000 additional deaths over the last four months. The downside risk to the rest of the country enduring a wave like Florida is frightening. In short, the delta variant has changed the stakes.

Should the FDA find that existing safety and efficacy data among COVID-19 vaccines in children meets FDA’s rigorous standards, issuing an emergency authorization for school aged children under 12 would be prudent. Children need to be in school, and learning in a safe environment. Thank you for your consideration and I am grateful for all of your work to help us achieve this critical goal.


Charlie Crist

Keep In Touch

Use the form below to sign up for my newsletter and get the latest news and updates directly to your inbox.

Office Locations